Cantor Fitzgerald reaffirmed their neutral rating on shares of Humana (NYSE:HUM – Free Report) in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a $290.00 price objective on the insurance provider’s stock. Cantor Fitzgerald also issued estimates for Humana’s FY2025 earnings at $16.27 EPS.
Other research analysts also recently issued research reports about the stock. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Morgan Stanley dropped their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Barclays lifted their price target on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Finally, TD Cowen upped their price objective on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $293.05.
Humana Stock Up 0.3 %
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts forecast that Humana will post 16.11 earnings per share for the current fiscal year.
Insider Activity
In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.32% of the company’s stock.
Institutional Trading of Humana
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC raised its stake in Humana by 6,647.5% during the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after acquiring an additional 26,856 shares during the last quarter. Retirement Systems of Alabama raised its stake in shares of Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after buying an additional 192,801 shares in the last quarter. PDT Partners LLC raised its stake in shares of Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after buying an additional 2,660 shares in the last quarter. Secure Asset Management LLC purchased a new position in shares of Humana during the 4th quarter worth approximately $244,000. Finally, Ontario Teachers Pension Plan Board raised its stake in shares of Humana by 6.5% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock worth $371,705,000 after buying an additional 71,910 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- Where to Find Earnings Call Transcripts
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- What Do S&P 500 Stocks Tell Investors About the Market?
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- How to trade using analyst ratings
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.